Vitamin C and cancer: what new research actually found

When Linus Pauling, a two-time Nobel laureate, argued in the 1970s that high-dose vitamin C could slow cancer growth, the claim sparked fierce scientific controversy. It was largely discredited after subsequent clinical trials using oral vitamin C pills showed no meaningful benefit for cancer patients.

For decades afterward, vitamin C was treated as a largely settled question in oncology circles — an idea tested and found wanting. Newer research, however, suggests Pauling's core intuition may not have been entirely wrong, only the delivery method.

The problem lies in digestion. Vitamin C taken orally is tightly regulated by the intestines, which cap how much reaches the bloodstream regardless of dose. That ceiling is far too low to meaningfully affect cancer cells.

Delivered intravenously, however, the picture changes entirely. Bypassing the gut altogether allows blood concentrations of vitamin C to reach levels hundreds of times higher than what oral supplementation can ever achieve.

At those extreme concentrations, vitamin C stops behaving like an ordinary nutrient and starts acting more like an experimental drug. Laboratory studies show these doses can generate hydrogen peroxide that selectively damages certain cancer cells.

Crucially, the effect appears to target vulnerable cancer cells while largely sparing healthy tissue — a difference researchers attribute to variation in cells' antioxidant defenses against oxidative stress.

Early-stage clinical research suggests that high-dose intravenous vitamin C, used alongside chemotherapy, may reduce certain treatment-related side effects and improve some patients' quality of life. Those findings, however, have not yet been confirmed in large, randomized controlled trials.

Experts broadly agree that current evidence is not sufficient to position vitamin C as a standalone cancer treatment. Instead, researchers describe its potential in more cautious terms — as a possible supportive addition alongside standard therapies.

The research also stands as a striking case study in how a respected scientist's idea can be revisited once the delivery method changes. Pauling's apparent error, in retrospect, was not in the underlying hypothesis but in how the compound was administered.

As larger trials proceed, it should become clearer whether intravenous vitamin C earns a standard place in oncology clinics as a supportive therapy. For now, the findings are described as promising but inconclusive, and researchers stress that patients should not attempt high-dose vitamin C on their own.